All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA450)

NICE GUIDANCE ISSUED JUNE 2017

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation

Advice No: 1916 – July 2016

Blinatumomab (Blincyto®▼) 38.5 micrograms powder for concentrate and solution for solution for infusion

Submission by Amgen Ltd.

Recommendation of AWMSG

Blinatumomab (Blincyto®▼) is recommended as an option for use within NHS Wales for the treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- AWMSG considered that blinatumomab (Blincyto®▼) satisfies the AWMSG criteria for ultra-orphan drug status.
- AWMSG acknowledged that the AWMSG criteria for appraising life-extending, end-of-life medicines applied to blinatumomab (Blincyto®▼) for the indication under consideration.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 589), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by the Welsh Government and will be considered for review every three years.

NICE accredited
www.nice.org.uk/accreditation

NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1916: Blinatumomab (Blincyto ®▼) 38.5 micrograms powder for concentrate and solution for solution for infusion. July 2016.